StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
0919.HK$0.10+0.00%
Fair $0.10+0.0%

0919.HK

Modern Healthcare Technology Holdings Limited

Consumer Cyclical / Personal ServicesHKSE

$0.10

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $0.10Fund rank 26/100 · Data gapFallback financials|
SA 55/C
F-Score: 6/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 32% · confianza 22%

FCF escenarios

weak_data · normalized FCF $125.5M · quality 44.3/100

Data gap 26/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 26/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

55/100

C

Piotroski

6/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific holding-company NAV/SOTP model required: targets are disabled until look-through holdings, debt and discount data exists. ROE is -2.7%, below the 5% threshold
Thesis & Journal · 0919.HKLocal privado en este navegador · Modern Healthcare Technology Holdings Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$89M

P/E

4.9x

↓

EV/EBITDA

-0.8x

↓

ROE

-2.7%

↓

Gross Margin

36.5%

↑

Debt/Equity

0.37

↓
52-Week Range$0
$0$0

TradingView lightweight chart

0919.HK price, volumen y niveles de valoración

Último $0.098Periodo -89.3%
Fair value: $0.098

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+8.4%

FCF CAGR

—

FCF margin

29.8%

FCF / Net income

-26.64x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $453.3M · net income $-5.1M · FCF $134.9M

2022-FY → 2025-FY

Gross margin

36.5%+10.9% pts

Operating margin

3.0%+19.7% pts

Net margin

-1.1%+18.2% pts

FCF margin

29.8%+38.1% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$453.3M$453.3M$454.7M$406.3M$355.6M
Net Income$-5.1M$-5.1M$-9.6M$-20.6M$-68.8M
EBITDA$77.1M$77.1M$73.0M$70.7M$26.4M
EPS-0.01-0.01-0.01-0.02-0.08
Gross Margin36.5%36.5%36.7%32.7%25.5%
Operating Margin3.0%3.0%2.1%-0.3%-16.7%
Net Margin-1.1%-1.1%-2.1%-5.1%-19.4%
Balance Sheet
Debt/Equity0.370.370.560.200.30
Current Ratio1.131.13———
Cash Flow
Free Cash Flow$134.9M$134.9M$64.1M$125.5M$-29.5M
Returns
ROE-2.7%-2.7%-5.1%-10.3%-31.3%
Valuation
P/E4.904.90———
EV/EBITDA-0.84-0.84-0.090.212.47
P/B0.480.480.400.730.56
Growth & Yield
Revenue Growth-0.3%-0.3%11.9%14.3%—
EPS Growth47.2%47.2%53.5%70.0%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +19.5%

Total return

+19.5%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.01 → -0.01

Residual

+19.5%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term+19.5%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.